Host Genetic Variation in Interferon Signaling and Its Influence on Febrile Illness Severity

Abstract

Febrile illnesses arise from diverse infectious and inflammatory triggers, yet clinical severity varies substantially among individuals with apparently similar exposures. Host genetic variation in interferon signaling is an important determinant of this heterogeneity. Interferons coordinate innate and adaptive antiviral defense through pathogen recognition receptors, Janus kinase and signal transducer and activator of transcription pathways, interferon-stimulated genes, and regulatory feedback mechanisms. Variants affecting these pathways may produce impaired pathogen control, excessive inflammation, delayed immune resolution, or altered responses to antiviral treatment. The clinical consequences range from self-limited fever to severe viral pneumonia, encephalitis, hemorrhagic disease, sepsis, and multiorgan dysfunction. This review summarizes the epidemiologic relevance, molecular mechanisms, clinical manifestations, diagnostic considerations, management implications, and emerging therapeutic strategies associated with host genetic variation in interferon biology. Integration of genomic data with clinical assessment, pathogen detection, and immune profiling may improve risk stratification and support more individualized treatment, although routine genetic testing remains limited by cost, turnaround time, population bias, and incomplete functional interpretation.

Introduction

Fever is a common manifestation of infection and systemic inflammation, but its severity and clinical trajectory are shaped by more than pathogen characteristics alone. Age, comorbid disease, inoculum, prior immunity, vaccination, nutritional status, microbiome composition, and access to care all influence outcomes. Increasing evidence indicates that inherited differences in immune pathways also contribute materially to susceptibility and disease severity. Interferon signaling is particularly important because it represents an early, highly conserved defense system that limits viral replication, activates natural killer cells, promotes antigen presentation, and influences the development of adaptive immunity.

Type I interferons, principally interferon-alpha and interferon-beta, and type III interferons, including interferon-lambda, are produced after recognition of microbial nucleic acids by receptors such as Toll-like receptors, RIG-I-like receptors, and cyclic GMP-AMP synthase pathways. Signaling through interferon receptors activates Janus kinase 1, tyrosine kinase 2, STAT1, STAT2, and interferon regulatory factor 9, generating transcriptional programs that induce antiviral proteins. Genetic variation at any stage of this process can modify the intensity, timing, or duration of the response. The result may be insufficient early control of infection or an exaggerated inflammatory state that contributes to tissue injury.

Epidemiology / Disease Burden

Severe febrile illness remains a major cause of emergency evaluation, hospitalization, and death worldwide. Respiratory viruses, arboviruses, hemorrhagic viruses, enteric pathogens, and invasive bacterial infections can all produce fever with systemic complications. During outbreaks, most infected people may experience mild disease while a smaller subgroup develops hypoxemic respiratory failure, shock, neurologic involvement, or multiorgan dysfunction. This clinical dispersion is consistent with a variable host response rather than pathogen burden alone.

Rare inborn errors of immunity affecting interferon production or signaling have provided direct evidence of causality. Defects involving TLR3, UNC93B1, TRIF, IRF3, IRF7, IFNAR1, IFNAR2, STAT1, STAT2, and related molecules have been associated with severe disease after exposure to otherwise common viral pathogens. In contrast, common regulatory variants may have smaller individual effects but collectively influence susceptibility across populations. The prevalence and clinical importance of these variants differ by ancestry, age group, pathogen, and environmental context. Population studies therefore require careful interpretation, particularly when findings from one ancestry group are generalized to another.

Pathophysiology

Interferon responses are governed by a balance between rapid pathogen restriction and controlled immune activation. Viral RNA or DNA is detected by intracellular and membrane-associated sensors, leading to activation of interferon regulatory factors and nuclear factor kappa B. Secreted interferons bind to cell-surface receptors and activate STAT-dependent transcription. Interferon-stimulated genes encode proteins that degrade viral RNA, inhibit translation, alter membrane trafficking, enhance natural killer cell activity, and improve recognition of infected cells.

Loss-of-function variants may impair interferon synthesis, receptor expression, signal transduction, or downstream gene activation. A patient with defective early signaling may have a high viral load before adaptive immunity develops, allowing infection to disseminate or cause extensive tissue damage. Some genetic defects are cell-type specific, whereas others produce broad susceptibility to multiple pathogens. Conversely, gain-of-function or regulatory variants can prolong interferon activity, promote endothelial activation, and increase expression of inflammatory mediators. Persistent interferon signaling may contribute to lymphocyte dysfunction, vascular injury, coagulopathy, and organ-specific immunopathology.

Autoantibodies that neutralize type I interferons represent an acquired, host-mediated disruption of the same pathway. Although not inherited genetic variants, they demonstrate how impaired interferon activity can produce severe febrile viral disease. Genetic predisposition may also interact with autoantibody formation, age-related immune remodeling, and prior infections. The timing of interferon activity is crucial: early signaling can be protective, whereas delayed or sustained signaling may intensify inflammatory injury. This temporal principle helps explain why therapeutic interferon effects depend on the pathogen, disease stage, route of administration, and immune phenotype.

Risk Factors

Risk is increased by extremes of age, pregnancy, immunosuppression, chronic pulmonary or cardiovascular disease, diabetes, renal dysfunction, obesity, malignancy, and delayed presentation. Genetic risk becomes especially relevant when severe disease occurs in a previously healthy person, when multiple family members develop unusually serious illness, or when recurrent severe infections involve a characteristic pathogen. Consanguinity, a history of childhood infections, unexplained encephalitis, and severe disease after live viral vaccination can provide additional clues to an inherited immune disorder.

Genetic susceptibility is rarely deterministic. Environmental exposure, pathogen genotype, viral dose, coinfection, vaccination status, and baseline inflammatory state can modify penetrance. A variant associated with severe disease in one infection may have little effect in another because pathogens use different entry pathways and evade immunity through distinct mechanisms. Clinicians should therefore avoid assigning causality solely on the basis of a genetic result without functional and clinical correlation.

Clinical Features

Patients may present with persistent high fever, rigors, malaise, myalgia, headache, cough, gastrointestinal symptoms, rash, cytopenias, or hemodynamic instability. Interferon pathway dysfunction can be suspected when febrile illness progresses rapidly despite supportive care, produces disproportionate viral replication, or involves the central nervous system, lungs, liver, or hematologic system. Severe respiratory disease may include hypoxemia and diffuse pneumonitis, while neurologic infection may manifest as seizures, encephalopathy, or focal deficits.

Laboratory abnormalities are nonspecific but may include lymphopenia, thrombocytopenia, elevated aminotransferases, increased ferritin, C-reactive protein elevation, coagulation abnormalities, and markers of renal or myocardial injury. A low inflammatory marker level does not exclude dangerous infection, particularly during early impaired innate responses. Conversely, substantial inflammation may reflect host-mediated injury rather than uncontrolled pathogen replication alone. Serial assessment is therefore more informative than a single measurement.

Diagnosis

Evaluation begins with syndrome recognition, complete exposure and family history, focused examination, and urgent assessment of airway, breathing, circulation, mental status, and organ perfusion. Microbiologic testing should be guided by the clinical syndrome and local epidemiology, using nucleic acid amplification, antigen testing, culture, serology, or metagenomic methods when appropriate. Imaging and targeted laboratory studies help identify pulmonary, neurologic, abdominal, or vascular complications.

Genetic testing is most valuable when severe or unusual infection is unexplained by common risk factors. A practical approach may include a focused primary immunodeficiency panel, interferon-related gene sequencing, copy-number analysis, and, when necessary, whole-exome or whole-genome sequencing. Interpretation should incorporate allele frequency, predicted molecular effect, segregation, functional assays, and established disease mechanisms. Immune phenotyping may include interferon-stimulated gene expression, cytokine production, receptor signaling studies, and testing for neutralizing interferon autoantibodies. Results should be reviewed with clinical immunology, genetics, infectious disease, and laboratory specialists.

Treatment & Management

Initial management follows established principles for severe febrile illness: rapid stabilization, appropriate isolation, prompt pathogen-directed testing, early antimicrobial therapy when bacterial infection is plausible, fluid and vasopressor support when indicated, oxygenation and ventilation strategies, and monitoring for organ dysfunction. Treatment should not be delayed while awaiting genetic results. Antiviral therapy is most effective when matched to the pathogen and started early, particularly in patients with risk factors for progression.

Immunomodulatory treatment requires careful phenotyping. Exogenous interferon may be considered in selected infections or defined signaling defects, but benefit depends on an intact downstream pathway and appropriate timing. In patients with excessive inflammation, corticosteroids, interleukin-directed agents, or other immunomodulators may be considered according to disease-specific evidence and specialist guidance. These treatments can reduce inflammatory injury but may worsen uncontrolled replication if administered indiscriminately. Therapeutic decisions should integrate pathogen load, oxygen requirement, inflammatory trajectory, organ involvement, and immune function.

Patients with confirmed inherited interferon disorders require long-term planning, including vaccination review, avoidance of selected live vaccines when contraindicated, family counseling, infection-prevention education, and individualized prophylaxis. Hematopoietic stem cell transplantation is appropriate for some severe combined or syndromic immunodeficiencies but is not a universal treatment for isolated interferon defects. Genetic counseling should address inheritance, reproductive implications, variant uncertainty, and the limitations of predictive testing.

Recent Advances / Emerging Therapies

Recent research has focused on rapid host-response profiling, functional genomics, and precision immune therapeutics. Transcriptomic signatures of interferon activation may help distinguish inadequate antiviral responses from hyperinflammatory states, although laboratory standardization remains incomplete. High-throughput cellular assays can assess receptor signaling and identify variants that appear benign or pathogenic based on actual biologic function. Multi-omic approaches combining genomics, transcriptomics, proteomics, and metabolomics may improve prediction of deterioration.

Emerging therapeutic concepts include early pathway-specific interferon supplementation, engineered interferon-lambda, targeted inhibition of harmful downstream inflammation, and replacement or correction strategies for defined molecular defects. Messenger RNA and gene-editing platforms are being investigated as potential ways to restore deficient immune functions, but delivery, immunogenicity, durability, and safety remain major barriers. Pharmacogenomic approaches may eventually guide antiviral selection and dosing, particularly when host variants alter drug metabolism or treatment response. These strategies require validation in prospective, diverse clinical cohorts before routine implementation.

Guideline Recommendations

Current clinical guidelines generally recommend syndrome-based evaluation, early pathogen-directed treatment, vaccination according to national schedules, and escalation of care for hypoxemia, shock, altered mental status, or rapidly progressive organ dysfunction. They support specialist referral for patients with unusually severe infections, recurrent opportunistic disease, strong family histories, or suspected inborn errors of immunity. Genetic testing should be performed with informed consent and interpreted alongside clinical and functional evidence.

Guideline-consistent care also requires antimicrobial stewardship, avoidance of unproven immunotherapies, and reassessment as diagnostic information evolves. Infection-control measures should reflect the suspected pathogen, while household members may need evaluation when a transmissible infection or inherited susceptibility is present. Multidisciplinary collaboration is recommended for complex cases involving infectious disease, intensive care, immunology, genetics, hematology, neurology, and pharmacy. Because evidence for rare interferon disorders is often derived from case series and mechanistic studies, individualized decisions and expert consultation remain essential.

Conclusion

Host genetic variation in interferon signaling is a clinically important contributor to the diverse severity of febrile illness. Defects in interferon production, receptor engagement, intracellular signaling, or downstream antiviral activity can permit uncontrolled infection, while excessive or prolonged signaling can promote inflammatory tissue injury. Recognition should be considered in previously healthy patients with unusually severe infection, recurrent characteristic illness, strong family history, or unexplained disease after common viral exposure. Immediate supportive and pathogen-directed treatment remains central, and genetic investigation should complement rather than delay acute care. Improved functional testing, equitable genomic databases, standardized immune profiling, and prospective clinical trials may enable more accurate risk prediction and safer precision therapies. A mechanistic understanding of interferon biology offers an important route toward reducing preventable morbidity and improving outcomes in severe febrile disease.